Biogen (NASDAQ: BIIB) grants 1,800 RSUs to Chief Accounting Officer

Rhea-AI Filing Summary

Godbout Sean reported acquisition or exercise transactions in this Form 4 filing.

Biogen Inc. Chief Accounting Officer Sean Godbout reported receiving a grant of 1,800 restricted stock units. These RSUs were awarded at a stated price of $0.00 per unit and increase his directly owned derivative holdings to 1,800 units. According to the footnote, the award vests in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026, meaning one-third of the units will vest each year over a three-year period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Godbout Sean

(Last) (First) (Middle)

225 BINNEY

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/13/2026		A		1,800		(1)	02/13/2029	Common Stock	1,800	$0	1,800	D

Explanation of Responses:

1. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.

	/s/ Wendell Taylor, attorney-in-fact for Mr. Godbout	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biogen (BIIB) Chief Accounting Officer Sean Godbout report?

Sean Godbout reported receiving a grant of 1,800 restricted stock units from Biogen. The units were awarded at a stated price of $0.00 per unit and are structured as equity compensation that vests over time rather than an immediate stock purchase or sale.

How many restricted stock units did Biogen (BIIB) award to Sean Godbout?

Biogen awarded 1,800 restricted stock units to Chief Accounting Officer Sean Godbout. These units represent a form of equity-based compensation and are scheduled to vest in stages, rather than becoming fully owned immediately on the grant date.

What is the vesting schedule for Sean Godbout’s Biogen (BIIB) restricted stock units?

The 1,800 restricted stock units vest in three equal yearly installments. Vesting starts on the first anniversary of the grant date of February 13, 2026, so one-third of the units becomes vested each year over a three-year period.

On what date were the new restricted stock units granted to Biogen (BIIB) executive Sean Godbout?

The restricted stock units were granted on February 13, 2026. This date also starts the clock for the vesting schedule, with the first one-third of the units vesting on the first anniversary of this grant date, then annually thereafter.

How many Biogen (BIIB) restricted stock units does Sean Godbout own after this Form 4 transaction?

After this transaction, Sean Godbout directly holds 1,800 restricted stock units. The Form 4 indicates that this total reflects his derivative holdings following the award, all subject to the three-year, equal-installment vesting schedule described in the accompanying footnote.

What type of security did Biogen (BIIB) grant to Sean Godbout in this insider filing?

Biogen granted restricted stock units, a type of equity-based derivative security. These units do not involve an immediate cash exercise price and instead convert into shares as they vest over three years, beginning February 13, 2026, according to the disclosed vesting schedule.